Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis

References

• ShariatSFSfakianosJPDrollerMJKarakiewiczPIMerynSBochnerBHThe effect of age and gender on bladder cancer: a critical review of the literatureBJU Int2010105330030819912200
   PubMed Web of Science ®Google Scholar
• SpiessPEAgarwalNBangsRBladder Cancer, Version 5. 2017, NCCN Clinical Practice Guidelines in OncologyJ Natl Compr Canc Netw201715101240126728982750
   PubMed Web of Science ®Google Scholar
• SternbergCNde MulderPSchornagelJHSeven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursEur J Cancer2006421505416330205
   PubMed Web of Science ®Google Scholar
• von der MaaseHHansenSWRobertsJTGemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III studyJ Clin Oncol200018173068307711001674
   PubMed Web of Science ®Google Scholar
• von der MaaseHSengelovLRobertsJTLong-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancerJ Clin Oncol200523214602460816034041
   PubMed Web of Science ®Google Scholar
• Perez-GraciaJLLoriotYRosenbergJEAtezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of RegimensEur Urol Epub20171219
   Google Scholar
• PowlesTDuranIvan der HeijdenMSAtezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialLancet20183911012274875729268948
   PubMed Web of Science ®Google Scholar
• NaikiTKawaiNHashimotoYGemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinomaInt J Clin Oncol201419351652223749066
   PubMed Web of Science ®Google Scholar
• SawhneyRSehlMNaeimAPhysiologic aspects of aging: impact on cancer management and decision making, part ICancer J200511644946016393479
   PubMedGoogle Scholar
• SehlMSawhneyRNaeimAPhysiologic aspects of aging: impact on cancer management and decision making, part IICancer J200511646147316393480
   PubMedGoogle Scholar
• CromePLallyFCherubiniAExclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT studyDrugs Aging201128866767721812501
   PubMed Web of Science ®Google Scholar
• PallisAGRingAFortpiedCEORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumorsAnn Oncol20112281922192621266517
   PubMed Web of Science ®Google Scholar
• HurriaALevitLADaleWImproving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology StatementJ Clin Oncol201533323826383326195697
   PubMed Web of Science ®Google Scholar
• CharlsonMEPompeiPAlesKLMackenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
   PubMedGoogle Scholar
• DreicerRManolaJSchneiderDJPhase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology GroupCancer200397112743274712767086
   PubMed Web of Science ®Google Scholar
• FléchonAFizaziKGourgou-BourgadeSGemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer CentersAnticancer Drugs200617670570816917216
   PubMed Web of Science ®Google Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• TrottiAColevasADSetserACTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSemin Radiat Oncol200313317618112903007
   PubMed Web of Science ®Google Scholar
• BellmuntJThéodoreCDemkovTPhase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tractJ Clin Oncol200927274454446119687335
   PubMed Web of Science ®Google Scholar
• SrinivasSHarshmanLCA phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinomaChemotherapy200955532132619641314
   PubMed Web of Science ®Google Scholar
• AlbersPParkSINiegischGRandomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]Ann Oncol201122228829420682548
   PubMed Web of Science ®Google Scholar
• SalahSLeeJLRozziASecond-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line StudiesClin Genitourin Cancer2017154e563e57128065418
   PubMed Web of Science ®Google Scholar
• SunLLuJNiuZA Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder CancerPLoS One20151012e014448426658059
   PubMed Web of Science ®Google Scholar
• NakanoTSaikiYKudoCAcquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCKBiochem Biophys Res Commun201546441084108926196746
   PubMed Web of Science ®Google Scholar
• DemolsAPeetersMPolusMGemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II studyBr J Cancer200694448148516434988
   PubMed Web of Science ®Google Scholar
• NaikiTIidaKKawaiNA pilot study of gemcitabine and paclitaxel as third-line chemotherapy in metastatic urothelial carcinomaJ Rural Med201712210511129255527
   PubMedGoogle Scholar
• KanaiKKikuchiEOhigashiTGemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapyInt J Clin Oncol200813651051419093178
   PubMed Web of Science ®Google Scholar
• KitamuraHTaguchiKKunishimaYPaclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC groupCancer Sci201110261171117521323791
   PubMed Web of Science ®Google Scholar
• KounoTAndoMYonemoriKWeekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum- based regimenEur Urol20075241115112217433855
   PubMed Web of Science ®Google Scholar
• MatsumotoKIrieASatohTOkazakiMIwamuraMBabaSGemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinomaInt J Urol2007141110001004 discussion 100417956525
   PubMed Web of Science ®Google Scholar
• IkedaMMatsumotoKTabataKCombination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapyJpn J Clin Oncol201141101214122021903707
   PubMed Web of Science ®Google Scholar
• YuenARZouGTurrisiATSimilar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinomaCancer20008991953196011064352
   PubMed Web of Science ®Google Scholar
• JanASDolanDELombardiKGuptaSTolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly PopulationClin Genitourin Cancer2016143e257e26326462439
   PubMed Web of Science ®Google Scholar
• PowlesTDuránIvan der HeijdenMSAtezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialLancet20183911012274875729268948
   PubMed Web of Science ®Google Scholar
• PowlesTO’DonnellPHMassardCEfficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label StudyJAMA Oncol201739e17241128817753
   PubMed Web of Science ®Google Scholar
• PatelMREllertonJInfanteJRAvelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trialLancet Oncol2018191516429217288
   PubMed Web of Science ®Google Scholar
• SharmaPRetzMSiefker-RadtkeANivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialLancet Oncol201718331232228131785
   PubMed Web of Science ®Google Scholar
• BellmuntJde WitRVaughnDJPembrolizumab as Second- Line Therapy for Advanced Urothelial CarcinomaN Engl J Med2017376111015102628212060
   PubMed Web of Science ®Google Scholar